Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Pliant Therapeutics Inc (PLRX)

90 + Investors. Track Smart Money conviction in PLRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
5Q ▼
Buyers last Q
49%

Smart Money Signals — PLRX

Based on 90 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds reduced or closed their PLRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🔻

Below peak — only 58% of 3.0Y high

58% of all-time peak
Only 90 funds hold PLRX today versus a peak of 155 funds at 2024 Q4 — just 58% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 34% fewer funds vs a year ago

fund count last 6Q
47 fewer hedge funds hold PLRX compared to a year ago (-34% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 49% buying

39 buying41 selling
Last quarter: 41 funds reduced or exited vs 39 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~14 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 24 → 12 → 14 → 14. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 29% medium ■ 19% new
47 out of 90 hedge funds have held PLRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

33 → 24 → 12 → 14 → 14 new funds/Q
New funds entering each quarter: 24 → 12 → 14 → 14. PLRX is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 65% veterans vs 27% newcomers

■ 65% veterans ■ 9% 1-2yr ■ 27% new
Entry-cohort mix of 94 holders: 61 (65%) are 2+ year veterans, 8 entered 1–2 years ago, and 25 (27%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 18% AUM from top-100

18% from top-100 AUM funds
23 of 90 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
1.4
out of 10
Low Exit Risk
Exit risk score 1.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PLRX

In 2026 Q1, 39 hedge funds were net buyers of PLRX (14 opened a new position, 25 added to an existing one), while 41 reduced or exited (25 trimmed, 16 sold completely) — a 49% buyer ratio, indicating roughly balanced activity. This extends a 5-quarter selling streak, suggesting sustained institutional caution. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 90.

Hedge Fund Ownership: PLRX

How many hedge funds hold PLRX — quarterly history vs. share price
Quarterly hedge fund ownership of PLRX vs. share price

Market Analysis: PLRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PLRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Pliant Therapeutics Inc (PLRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PLRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
PLRX
-6.3%
XLV
+2.8%

PLRX outperformed XLV by -9.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
PLRX
+2.6%
XLV
+3.9%

Since the filing became public, PLRX outperformed XLV by -1.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 1 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
1.4
/ 10
conviction
Hedge Fund Positioning: PLRX
90 + Investors

Track Smart Money conviction in PLRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 90 92 -2.17%
13F Shares 50M 47M 6.82%
Total Value $59M $57M 2.71%
New Positions 14 14 -
Increased Positions 24 31 -7
Closed Positions 16 17 -1
Reduced Positions 24 29 -5
Total Calls 2 2 -
Total Puts 2 2 -
PUT/CALL Ratio 1.0 1.0 Neutral

Statistics: PLRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

90 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PLRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PLRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Peapod Lane Capital LLC 1.30% 1,288,578 $1.6M
2 BML Capital Management, LLC 1.25% 1,546,137 $1.9M
3 Blue Owl Capital Holdings LP 1.01% 2,969,199 $3.7M
4 Monaco Asset Management SAM 0.45% 1,938,747 $2.4M
5 Tang Capital Management LLC 0.39% 6,143,132 $7.7M
6 Prosight Management, LP 0.34% 1,667,600 $2.1M
7 Nano Cap New Millennium Growth Fund L P 0.32% 275,000 $346K
8 Rangeley Capital, LLC 0.28% 225,000 $284K
9 ADAR1 Capital Management, LLC 0.19% 2,585,126 $3.3M
10 DAFNA Capital Management LLC 0.14% 487,000 $614K
11 Verdad Advisers, LP 0.14% 98,320 $124K
12 Stonepine Capital Management, LLC 0.11% 224,650 $283K
13 HighMark Wealth Management LLC 0.09% 166,224 $209K
14 Redmile Group, LLC 0.06% 772,126 $973K
15 Torno Capital, LLC 0.06% 350,000 $441K
16 Eversept Partners, LP 0.06% 891,425 $1.1M
17 Bond & Devick Financial Network, Inc. 0.04% 100,160 $126K
18 Laurion Capital Management LP 0.02% 412,796 $520K
19 Bridgeway Capital Management, LLC 0.01% 553,630 $698K
20 XTX Topco Ltd 0.01% 500,838 $631K
21 ArrowMark Colorado Holdings LLC 0.01% 281,189 $354K
22 Woodline Partners LP 0.01% 1,666,830 $2.1M
23 Hennion & Walsh Asset Management, Inc. 0.00% 106,705 $134K
24 Centiva Capital, LP 0.00% 432,525 $545K
25 Jacobs Levy Equity Management, Inc 0.00% 718,543 $905K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Pliant Therapeutics Inc (PLRX)

What does the Smart Money Trend signal show for PLRX?

Selling streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds reduced or closed their PLRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for PLRX?

More sellers than buyers — 49% buying: Last quarter: 41 funds reduced or exited vs 39 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for PLRX holders?

Smaller funds dominant — 18% AUM from top-100: 23 of 90 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held PLRX?

52% of holders stayed for 2+ years: 47 out of 90 hedge funds have held PLRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pliant Therapeutics Inc (PLRX) following the 2026 Q1 hedge fund 13F filings?

As of today, PLRX has moved +2.6% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -1.3%. Since the quarter end (March 31, 2026), PLRX has gained -6.3% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →